CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

PartnershipTPST-4003Positive
AI Analysis

Summary

Tempest Therapeutics announced a development collaboration with Senlang Biotechnology for TPST-4003, a CD7-targeted next-generation in vivo CAR-T therapy.

Importance:5/10
Sentiment:
0.50
partnershipcollaborationCAR-TimmunotherapyCD7
Related Companies

Read the original article

Published by yahoo_finance on July 21, 2026 11:00 AM

Read Original